New approaches to rewarding pharmaceutical innovation

Grootendorst, Paul; Hollis, Aidan; Levine, David K.; Pogge, Thomas; Edwards, Aled M.
April 2011
CMAJ: Canadian Medical Association Journal;4/5/2011, Vol. 183 Issue 6, p681
Academic Journal
The article offers information on the new patent approaches for pharmaceutical drug innovation. It mentions the proposed mechanisms which includes push programs, which is the public funding of basic research and clinical trials, and pull programs which include royalty-based schemes and reward-based schemes to develop the pharmaceutical current systems. It also discusses the limitations of the drug patent system, alternatives and complements to patents, and implementation of the issues.


Related Articles

  • INDUSTRY UPDATE - Lymphoma.  // PharmaWatch: Cancer;June 2003, Vol. 2 Issue 6, p8 

    No abstract available.

  • Overhauling clinical trials. Scott, Christopher Thomas; Baker, Monya // Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p287 

    The article examines the designs of clinical trials that adapt midstream which are billed as a cure for challenges in drug development. Drug companies do not apply adaptive designs to individual projects but spread them across their portfolios. The United States Food and Drug Administration...

  • Drug companies must report clinical trial results, even when they won't lead to a product.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p157 

    The article reports on the need for drug companies performing clinical trials to disclose the results of their research, even if they do not longer pursue product development.

  • Developing New Drugs in 1000 Days. Gugliotti, Jan // Applied Clinical Trials;Aug2002, Vol. 11 Issue 8, p44 

    Explores the implications of the speed and capacity in clinical trials of the U.S. competitive pharmaceutical industry for drug development. Innovation-driven improvement in clinical development time; New drug application approval time; Good laboratory practice. INSETS:...

  • Double Dip: Doctors Paid to Advise, Promote Drug Companies That Fund Their Research. Ornstein, Charles; Jones, Ryann Grochowski // Pro Publica;3/1/2014, p12 

    The article focuses on the stronger relationship between pharmaceutical companies and physicians in the U.S. It notes the willingness of pharmaceutical companies to pay for physicians who conduct their clinical trials and give speeches on behalf of their drugs. It also mentions the criticism of...

  • R&D UPDATE: Lung Cancer.  // PharmaWatch: Cancer;February 2003, Vol. 2 Issue 2, p5 

    Reports on developments of drugs for lung cancer treatment in the U.S. as of January 2003. Delay of the decision of the U.S. Food and Drug Administration (FDA) regarding the priority review of the new Iressa drug requested by AstraZeneca PLC; Announcement of the result of the phase I/II...

  • Rules of Automation. Koppal, Tanuja // Drug Discovery & Development;Aug2005, Vol. 8 Issue 8, p9 

    Focuses on the significance of automation in pharmaceutical processes. Role of automation in improving the quality of the products while reducing costs; Ability of automation in improving speed, increased accuracy, and heightened process efficiencies; Infiltration of automation in areas...

  • India and China attracting R&D spend from the West.  // Pharmaceutical Technology Europe;Jul2010, Vol. 22 Issue 7, p8 

    The article reports on the support for the drug discovery in India and China from the pharmaceutical research and development (R&D) in the West. Western countries see an opportunity on investing in the drug discovery in India and China due to its cost-saving offer. Moreover, both countries were...

  • Quality Issues for Multiregional Clinical-Trial Materials. Sandell, Dennis; Tougas, Terrence; O'Connor, Dennis; Horhota, Steve // Pharmaceutical Technology;Oct2011, Vol. 35 Issue 10, p124 

    The article offers information on the availability of opportunities in order to improve drug development process in clinical trials. Areas which would be beneficial for the drug development include modification of test products, genotoxic impurities and stability studies. The article further...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics